These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21087733)
1. Gene therapy for Parkinson's disease: do we have the cure? Benabid AL Lancet Neurol; 2010 Dec; 9(12):1142-1143. PubMed ID: 21087733 [No Abstract] [Full Text] [Related]
2. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Marks WJ; Bartus RT; Siffert J; Davis CS; Lozano A; Boulis N; Vitek J; Stacy M; Turner D; Verhagen L; Bakay R; Watts R; Guthrie B; Jankovic J; Simpson R; Tagliati M; Alterman R; Stern M; Baltuch G; Starr PA; Larson PS; Ostrem JL; Nutt J; Kieburtz K; Kordower JH; Olanow CW Lancet Neurol; 2010 Dec; 9(12):1164-1172. PubMed ID: 20970382 [TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Marks WJ; Ostrem JL; Verhagen L; Starr PA; Larson PS; Bakay RA; Taylor R; Cahn-Weiner DA; Stoessl AJ; Olanow CW; Bartus RT Lancet Neurol; 2008 May; 7(5):400-8. PubMed ID: 18387850 [TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease, primates, and gene therapy: vive la différence? Lewis TB; Standaert DG Mov Disord; 2011 Jan; 26(1):2-3. PubMed ID: 21322013 [No Abstract] [Full Text] [Related]
5. AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Kordower JH Methods Mol Biol; 2016; 1382():485-90. PubMed ID: 26611606 [TBL] [Abstract][Full Text] [Related]
7. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Bartus RT; Baumann TL; Brown L; Kruegel BR; Ostrove JM; Herzog CD Neurobiol Aging; 2013 Jan; 34(1):35-61. PubMed ID: 22926166 [TBL] [Abstract][Full Text] [Related]
8. [Advances in the application of gene therapy for Parkinson's disease with adeno-associated virus]. Chen Y; Lü YH; Li ZF Yao Xue Xue Bao; 2014 May; 49(5):576-81. PubMed ID: 25151724 [TBL] [Abstract][Full Text] [Related]
9. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Warren Olanow C; Bartus RT; Baumann TL; Factor S; Boulis N; Stacy M; Turner DA; Marks W; Larson P; Starr PA; Jankovic J; Simpson R; Watts R; Guthrie B; Poston K; Henderson JM; Stern M; Baltuch G; Goetz CG; Herzog C; Kordower JH; Alterman R; Lozano AM; Lang AE Ann Neurol; 2015 Aug; 78(2):248-57. PubMed ID: 26061140 [TBL] [Abstract][Full Text] [Related]
10. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Gasmi M; Herzog CD; Brandon EP; Cunningham JJ; Ramirez GA; Ketchum ET; Bartus RT Mol Ther; 2007 Jan; 15(1):62-8. PubMed ID: 17164776 [TBL] [Abstract][Full Text] [Related]
15. The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin. Wang W; Sun M; Li H; Wang W; Yan M Neurosci Lett; 2012 Aug; 524(1):10-5. PubMed ID: 22766137 [TBL] [Abstract][Full Text] [Related]
16. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Bartus RT; Baumann TL; Siffert J; Herzog CD; Alterman R; Boulis N; Turner DA; Stacy M; Lang AE; Lozano AM; Olanow CW Neurology; 2013 Apr; 80(18):1698-701. PubMed ID: 23576625 [TBL] [Abstract][Full Text] [Related]
17. Gene therapy for Parkinson's disease: still a hot topic? Kordower JH Neuropsychopharmacology; 2015 Jan; 40(1):255-6. PubMed ID: 25482182 [No Abstract] [Full Text] [Related]
18. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823 [TBL] [Abstract][Full Text] [Related]
19. AAV2-GDNF gene therapy for Parkinson's disease. Even Ram S; Galun E Hum Gene Ther; 2009 May; 20(5):430-1. PubMed ID: 19438403 [No Abstract] [Full Text] [Related]
20. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Bartus RT; Kordower JH; Johnson EM; Brown L; Kruegel BR; Chu Y; Baumann TL; Lang AE; Olanow CW; Herzog CD Neurobiol Dis; 2015 Jun; 78():162-71. PubMed ID: 25841760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]